CABALETTA BIO INC (CABA)
Health Care · CAR T cell therapy for autoimmune diseases · NASDAQ
Cabaletta Bio is a clinical-stage biotechnology firm developing one-time, curative CAR T cell therapies aimed at resetting the immune system for patients with complex autoimmune diseases.
What CABALETTA BIO INC does
Cabaletta Bio is a late clinical-stage biotechnology company developing innovative engineered T cell therapies targeting autoimmune diseases. The company's proprietary CABA platform focuses on the CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) approach, which is designed to reset the immune system through transient and deep B cell depletion. The lead product candidate, resecabtagene autoleucel (rese-cel), is a fully human CD19-CAR T construct being evaluated in multiple Phase 1/2 trials and a registrational trial across multiple autoimmune indications including myositis, systemic lupus erythematosus, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Themes: cell therapy, autoimmune disease / immunology, CAR-T immunotherapy, B cell depletion, regenerative medicine
Fundamentals
- Price$3.10 as of 2026-08-24 close
- Market cap$526M as of 2026-08-24
- 1-year return+91.4% 2025-08-22 close $1.62 → 2026-08-24 close $3.10
- P/En/a earnings data not available
- ROE-131.6% as of 2026-08-24
- Debt / equity0.23 as of 2026-08-24
- Beta1.80 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How CABA compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CABALETTA BIO INC looks technically
CABALETTA BIO INC (CABA) is trading 9.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 215 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 2 trading days ago. It is 26.0% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 9.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +9.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.88 | $2.88 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.86 | $2.86 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 36 calendar days ago — the swings before that are what the structure reading is measured on | 36 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 2.59. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 215 trading days ago — a "golden cross", a bullish long-term signal | 215 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 9.3% above | +9.3% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 22.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30) | 62.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($2.64 to $3.34) — its "stochastic" reading is 70 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 70.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 17 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $4.23 | $4.23 |
|---|---|---|
| From the 52-week high | it is 26.0% below its 52-week high (its highest price of the past year) | -26.0% |
| Above the 52-week low | it is 123.6% above its 52-week low (its lowest price of the past year) | +123.6% |
| Below the 52-week high | it is 26.0% below its highest point of the past year | 26.0% |
| Since a 20-day breakout | it made a new 20-day high about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 18 trading days ago | 18 sessions |
| All-time high | its highest closing price on record is $26.35 (set on 2024-02-08) | $26.35 |
| Given back of the 52-week move | over the past year its closes ranged ($1.45 to $4.15), and it has given back roughly a third of its rise from last year’s low — 38% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.40 to $2.48. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 37.8% |
| From the all-time high | it is 88.1% below its all-time high | -88.1% |
| Nearest price level | it is trading 6.6% below a resistance level at $3.34 — a price it turned at three times since 2025-10-09, most recently on 2026-07-06. Since 2024-08-21 it has 8 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +6.6% |
| All-time low | its lowest closing price on record is $0.59 (set on 2022-09-23) | $0.59 |
| Above the all-time low | it is 430.5% above its all-time low | +430.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 76% of it) | 24th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.189 between its high and its low — about 6.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.189 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.51 and $3.12 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.51 – $2.82 – $3.12 |
| Typical daily range (% of price) | its price moves about 6.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 1.4 daily ranges above its 200-day average price (9.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.20× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.9% since the prior reading | -0.9% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Open gap | it gapped 2.8% below the previous close 51 sessions ago and has not traded back through the level it left behind at 3.58 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.8% |
| Gap filled | a 2.3% gap down opened on 2026-07-17 has been "filled" 25 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 25 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 8.7 percentage points (the stock gained 11.0% while the market gained 2.3%) | +8.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 18.3 percentage points (the stock lost 15.2% while the market gained 3.1%) | -18.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 3.5 percentage points (the stock gained 7.6% while the market gained 11.1%) | -3.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 75.1 percentage points (the stock gained 95.6% while the market gained 20.5%) | +75.1% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: lagging the market over 6 months — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 12.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 1% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $3.09 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +1.4% |
|---|
Price levels it has turned at before
CABA last closed at $3.13 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.34 | Resistance | 6.6% above the last close | turned there three times · 2025-10-09 to 2026-07-06 |
| $2.89 | Support | 7.7% below the last close | turned there twice · 2025-01-07 to 2025-02-18 |
| $2.83 | Support | 9.4% below the last close | turned there twice · 2025-01-17 to 2026-06-26 |
| $3.53 | Resistance | 12.8% above the last close | turned there three times · 2024-11-01 to 2026-04-16 |
| $2.71 | Support | 13.5% below the last close | turned there twice · 2025-12-05 to 2026-04-30 |
| $3.81 | Resistance | 21.8% above the last close | turned there three times · 2024-09-25 to 2026-02-25 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $2.59.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 5 trading days, since 2026-08-17.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke out to a new 20-day high · Most volatile (6%+ typical daily range) · Trading at this year’s average price paid (anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$13.25 range $3.00 – $30.00; median $13.50
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CABA
- Consensus EPS estimate-$0.3059 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant reliance on the clinical success of a single lead product candidate, rese-cel.","History of operating losses and the expectation of continued future losses as development continues.","Potential for unexpected safety or efficacy issues in clinical trials or challenges with the scalability of the Cell Shuttle automated manufacturing process."]
What changed in the latest 10-Q
AI-assisted comparison of CABA's 10-Q filed 2026-05-14 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-14) describes rese-cel as being reviewed in February 2026 Nature Biotechnology publication alongside other commercial and academic constructs
- Newer filing reports December 2025 safety data: 95% of first 40 patients had no CRS or Grade 1 CRS, and 95% experienced no ICANS
- Newer filing states December 2025 initiation of registrational trial for dermatomyositis or anti-synthetase syndrome patients
- Newer filing mentions January 2026 IND clearance for automated manufacturing using Cellares' Cell Shuttle platform
- Newer filing reports April 2026 commercial supply agreement with Cellares for rese-cel manufacturing
- Newer filing references longer-term data from no-preconditioning SLE, LN and PV patients expected in second half of 2026
- Newer filing states RESET-Myositis registrational cohort planned size of 17 patients, based on treatment effect assumption and estimated background rate from retrospective analysis
- Removed:
- Older filing (2025-11-10) characterized company as 'clinical-stage'; newer filing states 'late clinical-stage'
- Older filing described platform as encompassing two strategies (CARTA and legacy CAART); newer filing states platform 'focuses on the CARTA approach' and removes mention of CAART legacy strategy
- Older filing mentioned MS IND clearance granted in January 2025; newer filing does not reference this
- Older filing stated RESET-Myositis affects approximately 85,000 patients in Europe; newer filing omits Europe patient count
- Older filing described trial as 'actively enrolling patients'; newer filing does not include this language
- Older filing stated 'at least six patients' per cohort; newer filing states specific numbers without 'at least'
- Older filing mentioned FDA alignment discussion and August 2025 feedback on registrational trial protocol; newer filing does not reference these interactions
- Older filing planned registrational cohort size of 14 patients; newer filing states 17 patients
- Older filing provided specific background rate examples (10% and 25%) with corresponding patient endpoint calculations; newer filing does not include these examples
- Reworded:
- Older: 'repopulation by healthy naïve B cells' changed to newer: 'repopulation by healthy transitional, naïve B cells'
- Older: 'has the potential to reset' changed to newer: 'has demonstrated the potential to reset'
- Older: 'RMAT, to rese-cel' changed to newer: 'RMAT, designation to rese-cel'
- Older: 'we are initiating a DM/ASyS registrational cohort' changed to newer: 'we initiated a registrational trial with rese-cel for patients with dermatomyositis or anti-synthetase syndrome'
- Older: 'Consistent with the previously announced FDA alignment on registrational cohort design...' language entirely removed in newer filing
- Older: 'The estimated background rate will be determined from an external myositis patient registry, as aligned with the FDA' changed to newer: 'The estimated background rate will be determined from a retrospective analysis of an external myositis patient registry'
- Notes:
- The newer filing text appears truncated at the end, cutting off mid-sentence regarding background rate discussion
- Direct comparison of complete registrational cohort rationale is limited due to text truncation in newer filing
Risk Factors
- Reworded:
- Reference to Annual Report on Form 10-K year changed from 'December 31, 2024' (filed 2025-11-10) to 'December 31, 2025' (filed 2026-05-14)
- Page number changed from '40' (filed 2025-11-10) to '36' (filed 2026-05-14) in the bullet point list section
- Notes:
- Both texts are truncated at the same point ('and, i'), preventing full comparison of subsequent content
- Substantive Risk Factors content appears identical between the two filings in the sections provided
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Most recent open-market transaction: 2026-01-21. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CABA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CABA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 5,453,435
- Reported value $14,669,740
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CABA had 40,777,017 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CABA had 24.1% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 18.45 days to cover at the same settlement.
- Reported short interest (shares) 40,777,017
- Short interest (% of shares outstanding) 24.1%
- Prior settlement (shares) 41,009,848
- Reported change -0.57%
- Days to cover (reported) 18.45
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Kyverna Therapeutics (KYTX)
- Fate Therapeutics (FATE)
- Intellia Therapeutics (NTLA)
- CRISPR Therapeutics (CRSP)
- Arcellx (ACLX)
- Bristol Myers Squibb (BMY)
- Novartis (NVS)
- Gilead Sciences (GILD)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CABA vs…
CABALETTA BIO INC is found in…
CABA ranks in…
Frequently asked questions
What does CABALETTA BIO INC (CABA) do?
Cabaletta Bio is a late clinical-stage biotechnology company developing innovative engineered T cell therapies targeting autoimmune diseases. The company's proprietary CABA platform focuses on the CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) approach, which is designed to reset the immune system through transient and deep B cell depletion.
What sector is CABALETTA BIO INC (CABA) in?
CABALETTA BIO INC (CABA) is classified in the Health Care sector. Its industry is CAR T cell therapy for autoimmune diseases. It trades on NASDAQ.
Who are CABALETTA BIO INC's (CABA) competitors?
Notable peers of CABALETTA BIO INC (CABA) include Kyverna Therapeutics, Fate Therapeutics, Intellia Therapeutics, CRISPR Therapeutics and Arcellx. This peer set is informational only — not financial advice.
Is CABALETTA BIO INC (CABA) overbought or oversold right now?
CABALETTA BIO INC (CABA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 62, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CABA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.